From the Journals

Patients with stage 1 NSCLC more likely to die of other causes in short term


 

FROM JOURNAL OF CLINICAL ONCOLOGY

Patients with stage 1 non–small cell lung cancer who underwent resection with intent to cure were more likely, over the short term, to die of other causes, investigators reported.

“Non–cancer-specific mortality represents a significant competing event for lung cancer–specific mortality, with an increasing impact as age increases,” Takashi Eguchi, MD, and his associates at Memorial Sloan Kettering Cancer Center, New York wrote (J Clin Oncol. 2016 Oct 10. doi: 10.1200/JCO.2016.69.0834).

“These findings can provide patients with more accurate information on survivorship on the basis of their individual preoperative status, and help determine patients’ optimal treatment options.”

The study included 2,186 patients who underwent curative-intent resection of stage 1 non-small cell lung cancer at Memorial Sloan Kettering between 2000 and 2011. The cumulative 5-year lung cancer death rate was 10.4%, but rose with age from 7.5% among patients younger than 65 years to 13.2% among patients who were at least 75 years old. Cumulative 5-year rates of mortality not due to cancer were lower, at 5.3% overall, 1.8% in the youngest cohort, and 9% in the oldest cohort. But a competing risk analysis of the entire cohort showed that non–cancer-specific cumulative mortality was higher than mortality from lung cancer for up to 1.5 years after resection, the investigators found. Furthermore, patients who were at least 75 years old were more likely to die of causes other than cancer for up to 2.5 years after surgery.

In the multivariable analysis, low predicted postoperative diffusing capacity of lung for carbon monoxide (DCLO) independently predicted severe morbidity (P less than .001), 1-year mortality (P less than .001), and non–cancer-specific mortality (P less than .001), the researchers said. These findings reflect prior work linking low DCLO with obstructive, restrictive, and pulmonary vascular disease, chronic heart failure, and poor postoperative outcomes, they noted.

Senior author Prasad S. Adusumilli, MD, provided funding. Dr. Eguchi and Dr. Adusumilli had no relevant financial disclosures.

Recommended Reading

IASLC lung cancer staging project proposes changes for new TNM classification
MDedge Hematology and Oncology
Esophagectomy 30-day readmission rate pegged at 19%
MDedge Hematology and Oncology
Wedge resection showed improved survival over SBRT for early-stage NSCLC
MDedge Hematology and Oncology
Early results positive for nivolumab as first-line therapy in advanced NSCLC
MDedge Hematology and Oncology
Biomarker-driven targeted therapy feasible for NSCLC
MDedge Hematology and Oncology
Pneumonitis with nivolumab treatment shows common radiographic patterns
MDedge Hematology and Oncology
Whole brain radiotherapy not beneficial for NSCLC metastasis
MDedge Hematology and Oncology
Data are mixed on cancerous transformation of cardiac mucosa in Barrett’s esophagus
MDedge Hematology and Oncology
New anticancer drugs linked to increased costs, life expectancy
MDedge Hematology and Oncology
NSCLC survival comparable with accelerated and conventional RT
MDedge Hematology and Oncology